Browsing by Author "Belaya, Zhanna"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Publication The effect of teriparatide treatment on the risk of fragility fractures in postmenopausal women with osteoporosis: Results from the asian and latin america fracture observational study (ALAFOS)(Springer, 2021-08-20) Chen, Chung-Hwan; Elsalmawy, Abdulaziz H.; Ish-Shalom, Sophia; Lim, Seung-Jae; AlAli, Nadia S.; Cunha-Borges, Joao L.; Yang, Huilin; Casas, Noemi; Altan, Lale; Belaya, Zhanna; Marin, Fernando; Moll, Thomas; Gurbuz, Sirel; Brnabic, Alan; Pavo, Imre; Florez, Sandra; Altan, Lale; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı; AAH-1652-2021The Asian and Latin America Fracture Observational Study (ALAFOS) is a prospective, observational, single-arm study conducted in 20 countries across Asia, Latin America and the Middle East. ALAFOS evaluated new clinical vertebral and non-vertebral fragility fractures in relation to time on teriparatide, in postmenopausal women with osteoporosis in real-life clinical practice. Clinical fragility fractures, back pain, and health-related quality of life (HRQoL) were recorded in 6-month intervals for <= 24 months during teriparatide treatment and up to 12-months post-treatment. Data were analysed with piecewise exponential regression with inverse probability weighting for time to event outcomes and mixed-model repeated measures for back pain and HRQoL. 3054 postmenopausal women started teriparatide and attended >= one follow-up visit (mean [SD] age 72.5 [10.4] years). The median (95% CI) time to treatment discontinuation was 22.0 months (21.2, 22.8). During the treatment period, 111 patients (3.6%) sustained 126 clinical fractures (2.98 fractures/100 patient-years). Rates of new clinical fragility fractures were significantly decreased during the > 6-12, > 12-18, and > 18-24-month periods, as compared with the first 6 months of treatment (hazard ratio [HR] 0.57; 95% CI 0.37, 0.88; p = 0.012; HR 0.35; 95% CI 0.19, 0.62; p < 0.001; HR 0.43; 95% CI 0.23, 0.83; p = 0.011; respectively). Patients also reported an improvement in back pain and HRQoL (p < 0.001). These results provide data on the real-world effectiveness of teriparatide in the ALAFOS regions and are consistent with other studies showing reduction of fractures after 6 months of teriparatide treatment. These results should be interpreted in the context of the noncontrolled design of this observational study.